{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:19:50Z","timestamp":1771474790043,"version":"3.50.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the molecular genetic characteristics of childhood acute lymphoblastic leukemia (ALL) and their relationships with clinical phenotypes, chromosomal abnormalities, and prognosis, so as to provide references for precise diagnosis and treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 302 newly diagnosed children with ALL were included. Real-time fluorescent quantitative PCR, high-throughput sequencing and other technologies were used to detect common fusion genes, rare fusion genes and Ph-like ALL-related molecules. Combined with chromosomal karyotype analysis, immunophenotyping and minimal residual disease (MRD) monitoring, the associations between molecular genetic characteristics and clinical indicators as well as prognosis were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 302 children, the total positive rate of leukemia genes was 50.66%, and the gene detection rate in B-ALL children (52.90%) was significantly higher than that in T-ALL (37.21%). Common fusion genes were mainly ETV6\/RUNX1 (19.54%), MLL (9.27%) and BCR\/ABL (6.29%), with age- and immune subtype-specific distributions. Children with ETV6\/RUNX1 positivity had the highest complete remission rate (93.2%) and the best 2-year event-free survival rate (89.8%), while those with BCR\/ABL positivity had the worst prognosis (complete remission rate 57.9%, 2-year event-free survival rate 42.1%). There were differences in the consistency between fusion genes and chromosomal abnormalities: ETV6\/RUNX1 and BCR\/ABL showed 100% consistency with specific chromosomal translocations, while E2A\/PBX1 and MLL showed about 50% consistency. The dynamic changes of MRD were closely related to gene types, with significantly higher MRD positive rates in children with high-risk genes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The molecular genetic characteristics of childhood ALL have clear clinical significance. Fusion gene detection can be used for disease classification, risk stratification and prognosis evaluation, providing an important basis for the formulation of individualized treatment strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1665431","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:02:25Z","timestamp":1761040945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular genetic characteristics and clinical significance of childhood acute lymphoblastic leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhenzhen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junchen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3390\/cancers14082021","article-title":"Recent advances in treatment options for childhood acute lymphoblastic leukemia","volume":"14","author":"Malczewska","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/cancers16040723","article-title":"Treatment of pediatric acute lymphoblastic leukemia: a historical perspective","volume":"16","author":"Hayashi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3390\/cells12030357","article-title":"The landscape of secondary genetic rearrangements in pediatric patients with B-cell acute lymphoblastic leukemia with t (12; 21)","volume":"12","author":"Kaczmarska","year":"2023","journal-title":"Cells"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.3390\/jcm10173792","article-title":"Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia","volume":"10","author":"Iacobucci","year":"2021","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood.2020010144","article-title":"Molecular classification improves risk assessment in adult BCR-ABL1\u2013negative B-ALL","volume":"138","author":"Paietta","year":"2021","journal-title":"Blood, J Am Soc Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"923419","DOI":"10.3389\/fped.2022.923419","article-title":"Novel treatments for pediatric relapsed or refractory acute B-cell lineage lymphoblastic leukemia: precision medicine era","volume":"10","author":"Mengxuan","year":"2022","journal-title":"Front Pediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"24290","DOI":"10.1038\/s41598-021-03709-7","article-title":"The association of complex genetic background with the prognosis of acute leukemia with ambiguous lineage","volume":"11","author":"Huang","year":"2021","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00428-022-03448-8","article-title":"International consensus classification of acute lymphoblastic leukemia\/lymphoma","volume":"482","author":"Duffield","year":"2023","journal-title":"Virchows Arch"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1182\/blood.2021012328","article-title":"Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno consortium","volume":"139","author":"Buchmann","year":"2022","journal-title":"Blood J Am Soc Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.3390\/cancers16223855","article-title":"Acute myeloid leukemia: diagnosis and evaluation by flow cytometry","volume":"16","author":"Ally","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000544969","article-title":"ISCN 2024: summary of revisions and new nomenclature","volume":"165","author":"Chia","year":"2025","journal-title":"Cytogenet Genome Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","article-title":"Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies","volume":"13","author":"Zehtabcheh","year":"2025","journal-title":"Biomark Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"114542","DOI":"10.1016\/j.ejmech.2022.114542","article-title":"Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update","volume":"239","author":"Engle","year":"2022","journal-title":"Eur J Med Chem"},{"key":"B14","unstructured":"Schneider\n              P\n            \n          \n          10.33540\/2070\n          Utrecht University\n          Towards unraveling the puzzle of KMT2A-rearranged infant acute lymphoblastic leukemia: novel insights into the relapse mechanisms, pathobiology, and therapeutic vulnerabilities\n          \n          2024"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1200\/JCO.20.03096","article-title":"Arsenic combined with all-trans retinoic acid for pediatric acute promyelocytic leukemia: report from the CCLG-APL2016 protocol study","volume":"39","author":"Zheng","year":"2021","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s12185-017-2206-4","article-title":"Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry","volume":"105","author":"Baraka","year":"2017","journal-title":"Int J Hematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/ijms21031054","article-title":"Minimal residual disease detection in acute lymphoblastic leukemia","volume":"21","author":"Kruse","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1182\/blood-2016-12-725804","article-title":"Minimal residual disease-directed therapy in childhood acute lymphoblastic leukemia: results of the AIEOP-BFM ALL 2000 study","volume":"129","author":"Campana","year":"2017","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41375-024-02272-0","article-title":"Analysis of measurable residual disease by IG\/TR gene rearrangements: quality assurance and updated EuroMRD guidelines","volume":"38","author":"van der Velden","year":"2024","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party. Blood","volume":"138","author":"Heuser","year":"2021","journal-title":"J Am Soc Hematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/ijc.33527","article-title":"Deleterious point mutations in T-cell acute lymphoblastic leukemia: mechanistic insights into leukemogenesis","volume":"149","author":"Roy","year":"2021","journal-title":"Int J Cancer"},{"key":"B22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-031-71180-0_2","article-title":"Genomic basis of B-cell precursor acute lymphoblastic leukemia","volume-title":"Acute Lymphoblastic Leukemia in Children and Adolescents. Pediatric Oncology","author":"Kimura","year":"2024"},{"key":"B23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.18502\/ijpho.v14i3.15992","article-title":"Analysis and identification of rare and prevalent breakpoints in chromosomal rearrangements in adult and pediatric with B-acute lymphoblastic leukemia (B-ALL): a systematic review","volume":"14","author":"Shahshahani","year":"2024","journal-title":"Iran J Ped Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/cells11061061","article-title":"One size does not fit all: heterogeneity in developmental hematopoiesis","volume":"11","author":"Barone","year":"2022","journal-title":"Cells"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3109\/10428194.2016.1141407","article-title":"B-cell acute lymphoblastic leukemia with mature phenotype and MLL rearrangement: report of five new cases and review of the literature","volume":"57","author":"Sajaroff","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/children12020166","article-title":"Microbiome modulation in pediatric leukemia: impact on graft-versus-host disease and treatment outcomes: a narrative review","volume":"12","author":"Todor","year":"2025","journal-title":"Children"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1186\/s12885-022-10378-w","article-title":"Prognostic value and outcome for acute lymphocytic leukemia in children with MLL rearrangement: a case-control study","volume":"22","author":"Qiu","year":"2022","journal-title":"BMC Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3390\/cancers13040777","article-title":"Infant acute myeloid leukemia: a unique clinical and biological entity","volume":"13","author":"Calvo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/jamaoncol.2021.6826","article-title":"Association of genetic ancestry with the molecular subtypes and prognosis of childhood acute lymphoblastic leukemia","volume":"8","author":"Lee","year":"2022","journal-title":"JAMA Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1126\/sciimmunol.aaq0015","article-title":"JAK-ing up treatment for CRLF2-R ALL","volume":"139","author":"Fielding","year":"2022","journal-title":"Blood, J Am Soc Hematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1182\/blood-2023-185799","article-title":"Uncovering the regulatory landscape of early human B-cell lymphopoiesis and its implications in the pathogenesis of B-cell acute lymphoblastic leukemia","volume":"142","author":"Planell","year":"2023","journal-title":"bioRxiv"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1610570","DOI":"10.3389\/pore.2022.1610570","article-title":"Case report: specific ABL-inhibitor imatinib is an effective targeted agent as the first line therapy to treat B-cell acute lymphoblastic leukemia with a cryptic NUP214: ABL1 gene fusion","volume":"28","author":"Stukaite-Ruibiene","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.3390\/ijms22063127","article-title":"Epigenetic control of infant B cell precursor acute lymphoblastic leukemia","volume":"22","author":"de Barrios","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-022-01251-1","article-title":"Targeting the histone H3 lysine 79 methyltransferase DOT1l in MLL-rearranged leukemias","volume":"15","author":"Yi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1101\/gad.2015411","article-title":"The super elongation complex (SEC) and MLL in development and disease","volume":"25","author":"Smith","year":"2011","journal-title":"Genes Dev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"10537","DOI":"10.1021\/acs.jmedchem.1c00037","article-title":"Targeting WD repeat-containing protein 5 (WDR5): a medicinal chemistry perspective","volume":"64","author":"Chen","year":"2021","journal-title":"J Med Chem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-biochem-051710-134100","article-title":"The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis","volume":"81","author":"Shilatifard","year":"2012","journal-title":"Annu Rev Biochem"},{"key":"B38","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3390\/life11080823","article-title":"Structure, activity and function of the MLL2 (KMT2B) protein lysine methyltransferase","volume":"11","author":"Klonou","year":"2021","journal-title":"Life"},{"key":"B39","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.celrep.2016.12.054","article-title":"MLL-AF4 spreading identifies binding sites that are distinct from super-enhancers and that govern sensitivity to DOT1l inhibition in leukemia","volume":"18","author":"Kerry","year":"2017","journal-title":"Cell Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1038\/onc.2016.488","article-title":"MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia","volume":"36","author":"Prange","year":"2017","journal-title":"Oncogene"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1128\/MCB.00182-12","article-title":"The super elongation complex family of RNA polymerase II elongation factors: gene target specificity and transcriptional output","volume":"32","author":"Luo","year":"2012","journal-title":"Mol Cell Biol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1331687","DOI":"10.3389\/fphar.2023.1331687","article-title":"Up-regulation of ABCG1 is associated with methotrexate resistance in acute lymphoblastic leukemia cells","volume":"14","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"12271","DOI":"10.3390\/ijms232012271","article-title":"Non-coding RNAs are implicit in chronic myeloid leukemia therapy resistance","volume":"23","author":"Rudich","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1442052","DOI":"10.3389\/fcell.2024.1442052","article-title":"Comprehensive summary: the role of PBX1 in development and cancers","volume":"12","author":"Liu","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/pharmaceutics14010215","article-title":"BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia","volume":"14","author":"Amarante-Mendes","year":"2022","journal-title":"Pharmaceutics"},{"key":"B46","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/bjh.17959","article-title":"Precursor B-cell acute lymphoblastic leukaemia\u2014a global view","volume":"196","author":"Biondi","year":"2022","journal-title":"Br J Haematol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1007\/s00277-023-05595-7","article-title":"The advances of E2A-PBX1 fusion in B-cell acute lymphoblastic leukaemia","volume":"103","author":"Yang","year":"2024","journal-title":"Ann Hematol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/lymphatics1020011","article-title":"Diagnosis and molecular pathology of lymphoblastic leukemias and lymphomas in the era of genomics and precision medicine: historical evolution and current concepts\u2014part 2: B-\/T-cell acute lymphoblastic leukemias","volume":"1","author":"Kansal","year":"2023","journal-title":"Lymphatics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1182\/bloodadvances.2016000463","article-title":"BCR-ABL1 gene rearrangement as a subclonal change in ETV6-RUNX1\u2013positive B-cell acute lymphoblastic leukemia","volume":"1","author":"Dun","year":"2016","journal-title":"Blood Adv"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1445794","DOI":"10.3389\/fonc.2024.1445794","article-title":"Current insights on m6A RNA modification in acute leukemia: therapeutic targets and future prospects","volume":"14","author":"Kaur","year":"2024","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.molcel.2022.02.013","article-title":"MLL: AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape","volume":"82","author":"Olsen","year":"2022","journal-title":"Mol Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cancergen.2013.01.004","article-title":"Simultaneous occurrence of ETV6-RUNX1 and BCR-ABL1 (e1a2) transcripts in a child with B-cell acute lymphoblastic leukemia","volume":"206","author":"Balatzenko","year":"2013","journal-title":"Cancer Genet"},{"key":"B53","first-page":"133","article-title":"Co-occurrence of ETV6::RUNX1 and P2RY8::CRLF2 fusion in a patient with relapsed acute B lymphoblastic leukemia","volume":"55","author":"Wu","year":"2025","journal-title":"Ann Clin Lab Sci"},{"key":"B54","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cancergen.2023.07.002","article-title":"Rare concomitance of ETV6:: RUNX1 and BCR: ABL1p210 in a child diagnosed with B-cell precursor acute lymphoblastic leukemia","volume":"276","author":"Barbosa","year":"2023","journal-title":"Cancer Genet"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.3390\/ijms23063067","article-title":"Resistance mechanisms in pediatric B-cell acute lymphoblastic leukemia","volume":"23","author":"J\u0119draszek","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B56","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3390\/biomedicines11030821","article-title":"Updates in KMT2A gene rearrangement in pediatric acute lymphoblastic leukemia","volume":"11","author":"G\u00f3recki","year":"2023","journal-title":"Biomedicines"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1080\/10428194.2018.1533127","article-title":"Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases","volume":"60","author":"Zhang","year":"2019","journal-title":"Leuk Lymphoma"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1665431\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:02:27Z","timestamp":1761040947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1665431\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":57,"alternative-id":["10.3389\/fped.2025.1665431"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1665431","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"article-number":"1665431"}}